Read NICE statement about the impact of COVID-19 on access to Spinraza.Read more
Wave Life Sciences have announced the disappointing news that the development of the drug suvodirsen for DMD has been discontinued.
The MDUK office will be closed during the Christmas period.
Sarepta’s exon skipping drug, VYONDYS 53™ (golodirsen) has been approved by the Food and Drug Administration (FDA). The FDA regulates drugs in the USA.
Preparatory work for the clinical trial is underway and progress is being made towards the development of next-generation microdystrophins.
NHS England and Patient Advocacy Groups have recently been focused on identification of hospitals with the right expertise to treat eligible adults who have SMA with nusinersen.
Six out of 10 supermarket chains do not have a single Changing Places toilet, according to research by Muscular Dystrophy UK.
Calls for cough assist machines to be NHS funded after Derby and Derbyshire CCG introduce new policy removing funding
World Toilet Day 2019 aims to raise awareness about the 2.6 billion people worldwide who don’t have access to toilets
The General Election is on 12 December 2019. We know that every day counts for people living with a muscle-wasting condition, but do all the Parliamentary candidates know that?
Britain’s top chefs on stage after creating a dinner, hosted by Prue Leith at Porchester Hall